High Thermostability and Lack of Cooperative DNA Binding Distinguish the p63 Core Domain from the Homologous Tumor Suppressor p53*

The p53 protein is the major tumor suppressor in mammals. The discovery of the p53 homologs p63 and p73 defined a family of p53 members with distinct roles in tumor suppression, differentiation, and development. Here, we describe the biochemical characterization of the core DNA-binding domain of a human isoform of p63, p63-δ, and particularly novel features in comparison with p53. In contrast to p53, the free p63 core domain did not show specific binding to p53 DNA consensus sites. However, glutathioneS-transferase-fused and thus dimerized p63 and p53 core domains had similar affinity and specificity for the p53 consensus sites p21, gadd45, cyclin G, andbax. Furthermore, the fold of p63 core was remarkably stable compared with p53 as judged by differential scanning calorimetry (T m = 61 °C versus 44 °C for p53) and equilibrium unfolding ([urea]50% = 5.2 m versus 3.1 m for p53). A homology model of p63 core highlights differences at a segment near the H1 helix hypothetically involved in the formation of the dimerization interface in p53, which might reduce cooperativity of p63 core DNA binding compared with p53. The model also shows differences in the electrostatic and hydrophobic potentials of the domains relevant to folding stability.

[1]  H. Edelhoch,et al.  Spectroscopic determination of tryptophan and tyrosine in proteins. , 1967, Biochemistry.

[2]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[3]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.

[4]  W. Kabsch,et al.  Dictionary of protein secondary structure: Pattern recognition of hydrogen‐bonded and geometrical features , 1983, Biopolymers.

[5]  A. Levine,et al.  Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53 , 1983, Molecular and cellular biology.

[6]  W. Maltzman,et al.  UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells , 1984, Molecular and cellular biology.

[7]  C. Pace Determination and analysis of urea and guanidine hydrochloride denaturation curves. , 1986, Methods in enzymology.

[8]  R Langridge,et al.  Improvements in protein secondary structure prediction by an enhanced neural network. , 1990, Journal of molecular biology.

[9]  M. W. Pandit,et al.  Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting in vivo stability of a protein from its primary sequence. , 1990, Protein engineering.

[10]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[11]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[12]  D. Lane,et al.  Regulation of the specific DNA binding function of p53 , 1992, Cell.

[13]  K. Kinzler,et al.  Definition of a consensus binding site for p53 , 1992, Nature Genetics.

[14]  J. Shay,et al.  A transcriptionally active DNA-binding site for human p53 protein complexes , 1992, Molecular and cellular biology.

[15]  G. Böhm,et al.  Quantitative analysis of protein far UV circular dichroism spectra by neural networks. , 1992, Protein engineering.

[16]  C. Pabo,et al.  The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. , 1993, Genes & development.

[17]  J. E. Stenger,et al.  p53 domains: identification and characterization of two autonomous DNA-binding regions. , 1993, Genes & development.

[18]  X. Chen,et al.  A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. , 1993, Genes & development.

[19]  A. Fersht,et al.  Engineered disulfide bonds as probes of the folding pathway of barnase: increasing the stability of proteins against the rate of denaturation. , 1993, Biochemistry.

[20]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[21]  R D Appel,et al.  A new generation of information retrieval tools for biologists: the example of the ExPASy WWW server. , 1994, Trends in biochemical sciences.

[22]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[23]  C. Arrowsmith,et al.  Solution structure of the tetrameric minimum transforming domain of p53 , 1995, Nature Structural Biology.

[24]  P. Tegtmeyer,et al.  Interaction of p53 with its consensus DNA-binding site , 1995, Molecular and cellular biology.

[25]  G. Marius Clore,et al.  Refined solution structure of the oligomerization domain of the tumour suppressor p53 , 1995, Nature Structural Biology.

[26]  T. Halazonetis,et al.  The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. , 1995, The EMBO journal.

[27]  P. Tegtmeyer,et al.  Role of cysteine residues in regulation of p53 function , 1995, Molecular and cellular biology.

[28]  A A Salamov,et al.  Prediction of protein secondary structure by combining nearest-neighbor algorithms and multiple sequence alignments. , 1995, Journal of molecular biology.

[29]  A. Gronenborn,et al.  Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  N. Pavletich,et al.  Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms , 1995, Science.

[31]  N. Pavletich,et al.  Structure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2 , 1996, Science.

[32]  T. Soussi,et al.  Structural aspects of the p53 protein in relation to gene evolution: a second look. , 1996, Journal of molecular biology.

[33]  D. Lane,et al.  Allosteric Regulation of the Thermostability and DNA Binding Activity of Human p53 by Specific Interacting Proteins (*) , 1996, The Journal of Biological Chemistry.

[34]  C. Arrowsmith,et al.  New insights into p53 function from structural studies. , 1996, Oncogene.

[35]  T. Halazonetis,et al.  Structure–based rescue of common tumor–derived p53 mutants , 1996, Nature Medicine.

[36]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[37]  A. Yang,et al.  Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.

[38]  M. Oren,et al.  Mdm2 promotes the rapid degradation of p53 , 1997, Nature.

[39]  V. Zhurkin,et al.  Architectural Accommodation in the Complex of Four p53 DNA Binding Domain Peptides with the p21/waf1/cip1 DNA Response Element* , 1997, The Journal of Biological Chemistry.

[40]  Stephen N. Jones,et al.  Regulation of p53 stability by Mdm2 , 1997, Nature.

[41]  W. Kaelin,et al.  p73 is a human p53-related protein that can induce apoptosis , 1997, Nature.

[42]  A. Fersht,et al.  Thermodynamic stability of wild-type and mutant p53 core domain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  A. Levine p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[44]  C. Bamberger,et al.  A novel protein with strong homology to the tumor suppressor p53 , 1997, Oncogene.

[45]  A. Fersht,et al.  Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  J. Boeke,et al.  Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations , 1998, The EMBO journal.

[47]  K. McLure,et al.  How p53 binds DNA as a tetramer , 1998, The EMBO journal.

[48]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[49]  Chikashi Ishioka,et al.  Cloning and functional analysis of human p51, which structurally and functionally resembles p53 , 1998, Nature Medicine.

[50]  J. Jen,et al.  A new human p53 homologue , 1998, Nature Medicine.

[51]  C. Prives Signaling to p53 Breaking the MDM2–p53 Circuit , 1998, Cell.

[52]  Xinbin Chen,et al.  The potential tumor suppressor p73 differentially regulates cellular p53 target genes. , 1998, Cancer research.

[53]  H. Kato,et al.  A second p53-related protein, p73L, with high homology to p73. , 1998, Biochemical and biophysical research communications.

[54]  H. Vogel,et al.  p63 is a p53 homologue required for limb and epidermal morphogenesis , 1999, Nature.

[55]  B. Foster,et al.  Pharmacological rescue of mutant p53 conformation and function. , 1999, Science.

[56]  D. Xirodimas,et al.  Molecular Evolution of the Thermosensitive PAb1620 Epitope of Human p53 by DNA Shuffling* , 1999, The Journal of Biological Chemistry.

[57]  C. Arrowsmith,et al.  Solution structure of a conserved C‐terminal domain of p73 with structural homology to the SAM domain , 1999, The EMBO journal.

[58]  K. Kinzler,et al.  Identification and classification of p53-regulated genes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[59]  M Bycroft,et al.  Hot-spot mutants of p53 core domain evince characteristic local structural changes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Michael Bamshad,et al.  Heterozygous Germline Mutations in the p53 Homolog p63 Are the Cause of EEC Syndrome , 1999, Cell.

[61]  S. Kato,et al.  The transcriptional activities of p53 and its homologue p51/p63: similarities and differences. , 1999, Cancer research.

[62]  C. Prives,et al.  p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells , 1999, Molecular and Cellular Biology.

[63]  W. Kaelin The p53 gene family , 1999, Oncogene.

[64]  C. Arrowsmith Structure and function in the p53 family , 1999, Cell Death and Differentiation.

[65]  G. Melino,et al.  Structure, function and regulation of p63 and p73 , 1999, Cell Death and Differentiation.

[66]  Margaret Ashcroft,et al.  Regulation of p53 stability , 1999, Oncogene.

[67]  Christopher P. Crum,et al.  p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development , 1999, Nature.

[68]  A. Ellington,et al.  In vitro evolution of thermostable p53 variants , 2008, Protein science : a publication of the Protein Society.

[69]  B. Kennedy,et al.  NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. , 2000, Genes & development.

[70]  V. Rotter,et al.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. , 2000, Cancer research.

[71]  A. Yang,et al.  p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours , 2000, Nature.

[72]  A. Yang,et al.  p63 and p73: p53 mimics, menaces and more , 2000, Nature Reviews Molecular Cell Biology.

[73]  K. Vousden,et al.  Regulation and function of the p53-related proteins: same family, different rules. , 2000, Trends in cell biology.

[74]  A. Fersht,et al.  Mechanism of rescue of common p53 cancer mutations by second‐site suppressor mutations , 2000, The EMBO journal.

[75]  A. Fersht,et al.  Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy , 2000, Oncogene.

[76]  P. Hainaut,et al.  Redox signalling and transition metals in the control of the p53 pathway. , 2000, Biochemical pharmacology.

[77]  K. Vousden,et al.  Minireviewp 53 : Death Star able to induce the defensive p 53 response to oncogene , 2000 .

[78]  F. McKeon,et al.  An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. , 2000, Science.

[79]  J. Jen,et al.  AIS is an oncogene amplified in squamous cell carcinoma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[80]  G Melino,et al.  The p53/p63/p73 family of transcription factors: overlapping and distinct functions. , 2000, Journal of cell science.

[81]  A. Levine,et al.  Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73* , 2000, The Journal of Biological Chemistry.

[82]  R. Jaenicke,et al.  Stability and stabilization of globular proteins in solution. , 2000, Journal of biotechnology.

[83]  Xiaoqi Wang,et al.  MDM2 and MDMX can interact differently with ARF and members of the p53 family , 2001, FEBS letters.

[84]  J. Manfredi,et al.  The Tumor Suppressor Protein p53 Requires a Cofactor to Activate Transcriptionally the Human BAX Promoter* , 2001, The Journal of Biological Chemistry.

[85]  B. Trink,et al.  p53 associates with and targets ΔNp63 into a protein degradation pathway , 2001 .

[86]  R. Marmorstein,et al.  Crystal Structure of the Mouse p53 Core DNA-binding Domain at 2.7 Å Resolution* , 2001, The Journal of Biological Chemistry.

[87]  G. Blandino,et al.  From p63 to p53 across p73 , 2001, FEBS letters.

[88]  Yu Wai Chen,et al.  Structure of the C-terminal sterile α-motif (SAM) domain of human p73α , 2001 .

[89]  C. Prives,et al.  A Subset of Tumor-Derived Mutant Forms of p53 Down-Regulate p63 and p73 through a Direct Interaction with the p53 Core Domain , 2001, Molecular and Cellular Biology.